Advanced Pathology Solutions Set Up 'Lean Labs' Inside Doctors' Offices. Regulators Called It a Kickback.

Advanced Pathology Solutions PLLC and its former owners have agreed to pay $30 million to resolve three whistleblower lawsuits alleging the pathology company paid illegal kickbacks to gastroenterology practices in exchange for exclusive patient referrals, structured through in-office laboratories the company itself managed.DOCUMENTED

As part of the resolution, Advanced Pathology Solutions, commonly known as APS, entered a five-year Corporate Integrity Agreement requiring an ongoing compliance program, staff training, and independent review of its physician referral relationships.DOCUMENTED

What a "lean lab" actually was

According to the complaint in intervention, from 2015 through July 2022 APS knowingly and intentionally paid gastroenterology practices illegal compensation in exchange for patient referrals, structured through limited-purpose laboratories the complaint calls "lean labs."DOCUMENTED APS managed these labs within the gastroenterology practices themselves, and the arrangement allowed the practices to bill separately for preparing and staining biopsy specimen slides — a technical, billable step in the pathology process — while the practices, in turn, agreed to exclusively send patients' slides to APS for the pathologist's actual interpretation and review.DOCUMENTED

Because those services were paid for by federal health care programs, the arrangement fell within the reach of the Anti-Kickback Statute, which prohibits offering or receiving anything of value in exchange for referrals of services reimbursed by Medicare or other federal programs.DOCUMENTED The lean-lab structure gave referring physicians a direct financial stake in each biopsy slide sent to APS, since the practice itself earned a separate technical billing fee on every referral before APS ever performed its own interpretation.REVIEWED

A second allegation about commission structure

The settlement separately resolves allegations that for a two-year period ending in 2020, APS and its CEO, Kevin Hannah, provided unlawful kickbacks in the form of volume-based commission payments designed to reward continued referral volume from participating practices, independent of the lean-lab arrangement.DOCUMENTED Volume-based compensation tied directly to referral counts is a structure the Anti-Kickback Statute treats with particular scrutiny, since it creates a direct financial incentive for a referring party to send more business regardless of whether doing so reflects genuine clinical judgment about where a patient's samples should be sent.REVIEWED

The practices earned a separate billing fee on every slide they sent — meaning each referral to Advanced Pathology Solutions carried a direct financial benefit for the referring physician before any actual pathology work took place.

What the resolution requires going forward

Beyond the $30 million payment, the five-year Corporate Integrity Agreement obligates APS to maintain a compliance program, provide ongoing staff training and education, and submit its physician referral relationships to independent review — a structure designed to give federal health regulators continued visibility into the company's referral arrangements well after the settlement itself is finalized.DOCUMENTED Corporate Integrity Agreements of this kind function as an alternative to outright exclusion from federal health programs, giving a company a defined path to remain a Medicare and Medicaid participant provided it submits to sustained oversight.REVIEWED

Why in-office lab arrangements draw sustained scrutiny

The lean-lab model at the center of this case reflects a recurring structure regulators have targeted repeatedly in laboratory-referral enforcement: rather than a direct cash payment for referrals, which is comparatively easy to identify and prosecute, the arrangement channels value to the referring party through a legitimate-seeming billing mechanism embedded inside their own practice.REVIEWED That structure can make violations harder to detect from the outside, since the referring practice is genuinely performing a billable service — preparing and staining slides — even as the broader arrangement functions as compensation for directing the more lucrative interpretation work to a specific pathology partner.REVIEWED

Because the settlement resolves claims brought under the False Claims Act's whistleblower provisions, private relators who brought the underlying lawsuits will share in a portion of the $30 million recovery, consistent with the law's structure for rewarding individuals with inside knowledge of health care billing arrangements who come forward.REVIEWED

The role of a Corporate Integrity Agreement

A Corporate Integrity Agreement is a legally binding compliance arrangement the federal government imposes on health care providers as an alternative to program exclusion, typically requiring independent claims review, employee training, and regular reporting to the Department of Health and Human Services' Office of Inspector General.REVIEWED For APS specifically, the five-year term means the company's physician referral relationships — the exact category of arrangement at issue in this case — will remain subject to independent auditing well beyond the immediate settlement, giving regulators a structured mechanism to catch any recurrence of similar kickback arrangements before they grow to the scale alleged in this case.REVIEWED

The Justice Department noted that tips about potential health care fraud, waste, or abuse can be reported to HHS-OIG directly, a channel that in cases like this one has historically served as the starting point for whistleblower lawsuits brought by former employees or business associates with direct knowledge of a company's referral practices.REVIEWED As with other False Claims Act settlements, the claims resolved here are allegations only, and the resolution does not constitute a court determination that APS or Hannah violated the law. The size of the recovery, and the multi-year compliance term attached to it, nonetheless signal how seriously the government treats referral arrangements structured through ostensibly legitimate in-office billing mechanisms rather than direct cash payments. Health care providers reviewing their own referral relationships with outside labs or specialty practices may want to examine whether any billing arrangement effectively rewards volume, regardless of how the mechanism is structured on paper. That review can be a useful compliance exercise even for practices with no reason to suspect wrongdoing, given how easily a well-intentioned billing arrangement can drift toward the structure regulators flagged in this case.REVIEWED

Have documents relevant to this story? Reach us through our tips channel.